Zymergen, one of the companies that’s developing biomanufacturing technologies that could reshape any number of industries, said it has raised $300 million in financing. It’s part of a wave of biotech companies that TechCrunch covered in depth last month. Synthetic biology startups are giving investors an appetite The investment total, announced yesterday, includes Series D … Continue reading Zymergen raised $300 million because synthetic biology is so hot right now